Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials

[1]  John O. Konz,et al.  Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials , 2020, The Lancet.

[2]  L. Roberts.  The polio eradication campaign is faltering. Can a new vaccine help it get back on track? , 2020 .

[3]  K. Badizadegan,et al.  Updated Characterization of Outbreak Response Strategies for 2019–2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain , 2020, Risk analysis : an official publication of the Society for Risk Analysis.

[4]  A. Irwin.  New polio vaccine poised to get emergency WHO approval , 2020, Nature.

[5]  V. Usonis,et al.  A Randomized Phase 4 Study of Immunogenicity and Safety After Monovalent Oral Type 2 Sabin Poliovirus Vaccine Challenge in Children Vaccinated with Inactivated Poliovirus Vaccine in Lithuania , 2020, The Journal of infectious diseases.

[6]  O. Diop,et al.  Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, July 2019–February 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[7]  John O. Konz,et al.  Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence , 2020, Cell host & microbe.

[8]  R. Andino,et al.  Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization , 2020, npj Vaccines.

[9]  N. Grassly,et al.  Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine , 2020, Science.

[10]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[11]  M. Pallansch,et al.  Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, January 2018–June 2019 , 2019, MMWR. Morbidity and mortality weekly report.

[12]  John O. Konz,et al.  The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study , 2019, The Lancet.

[13]  L. Hampton,et al.  Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016. , 2016, MMWR. Morbidity and mortality weekly report.

[14]  S. Self,et al.  Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial , 2016, The Lancet.

[15]  S. Self,et al.  Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. , 2015, The Lancet. Infectious diseases.

[16]  R. Sutter,et al.  Vaccine-derived polioviruses. , 2014, The Journal of infectious diseases.

[17]  M. Pallansch,et al.  Standardized Methods for Detection of Poliovirus Antibodies. , 2016, Methods in molecular biology.